June 29, 2012 — A single 32-mg intravenous dose of ondansetron (Zofran, GlaxoSmithKline [ondansetron hydrochloride], and generics) may affect QT interval prolongation, the US Food and Drug ...
The FDA is informing healthcare professionals that preliminary results from a recently completed clinical study suggest that a 32mg single intravenous dose of ondansetron (Zofran; GlaxoSmithKline and ...
Rockville, MD - Clinicians should avoid using the antinausea drug ondansetron (Zofran, GlaxoSmithKline) in patients with congenital long-QT syndrome because they face an increased risk for torsades de ...
Preliminary results from a recent clinical study suggest that a 32-mg single IV dose of ondansetron may affect QT prolongation, which could predispose patients to develop torsades de pointes. The FDA ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Drugs that prolong the QT interval may increase the risk ...
17 August 2012, USA, California( Xmaspharmacy.com): The FDA (Food and Drug Administration) has reported GlaxoSmithKline (GSK) pharmaceutical company to make some changes to the labels of its drug ...
Use caution before prescribing ondansetron in patients on dialysis, and consider baseline and monitoring electrocardiograms in initiators. Oral ondansetron increases the risk of sudden cardiac death ...
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA Correspondence to Dr M J Ackerman, Long QT Syndrome Clinic and the Mayo Clinic Windland Smith ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results